SEQUENT SCIENTIFIC
|
SEQUENT SCIENTIFIC Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -1.44 | -4.86 | 1.65 | 3.84 | 2.81 |
| CEPS(Rs) | 1.28 | -2.66 | 3.88 | 6.24 | 5.34 |
| DPS(Rs) | - | - | - | 0.50 | - |
| Book NAV/Share(Rs) | 23.22 | 25.76 | 25.97 | 28.98 | 27.10 |
| Tax Rate(%) | 45.81 | 11.39 | 15.43 | 23.55 | 12.79 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 4.35 | 0.82 | 7.59 | 15.13 | 14.14 |
| EBIT Margin(%) | -0.46 | -7.02 | 4.76 | 11.60 | 10.77 |
| Pre Tax Margin(%) | -3.87 | -9.47 | 3.67 | 9.84 | 7.81 |
| PAT Margin (%) | -2.10 | -8.39 | 3.10 | 7.53 | 6.81 |
| Cash Profit Margin (%) | 2.26 | -4.56 | 6.68 | 11.17 | 11.01 |
| Performance Ratios | |||||
| ROA(%) | -2.01 | -8.21 | 3.06 | 7.19 | 5.73 |
| ROE(%) | -4.85 | -18.95 | 6.56 | 15.00 | 12.06 |
| ROCE(%) | -0.60 | -9.71 | 7.01 | 16.24 | 12.59 |
| Asset Turnover(x) | 0.96 | 0.98 | 0.98 | 0.96 | 0.84 |
| Sales/Fixed Asset(x) | 1.49 | 1.65 | 1.83 | 1.83 | 1.72 |
| Working Capital/Sales(x) | 7.67 | 6.58 | 5.32 | 5.47 | 5.75 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.67 | 0.61 | 0.55 | 0.55 | 0.58 |
| Receivable days | 87.51 | 84.11 | 85.48 | 87.43 | 90.45 |
| Inventory Days | 89.54 | 87.10 | 77.50 | 63.61 | 63.56 |
| Payable days | 121.21 | 109.97 | 111.61 | 117.51 | 129.62 |
| Valuation Parameters | |||||
| PER(x) | - | - | 81.14 | 62.69 | 27.61 |
| PCE(x) | 90.08 | -27.32 | 34.51 | 38.59 | 14.55 |
| Price/Book(x) | 4.96 | 2.82 | 5.15 | 8.31 | 2.87 |
| Yield(%) | - | - | - | 0.21 | - |
| EV/Net Sales(x) | 2.38 | 1.52 | 2.53 | 4.52 | 1.86 |
| EV/Core EBITDA(x) | 45.01 | 118.11 | 29.76 | 27.91 | 12.18 |
| EV/EBIT(x) | -496.55 | -21.21 | 52.09 | 38.21 | 16.93 |
| EV/CE(x) | 2.94 | 1.98 | 2.41 | 4.26 | 1.50 |
| M Cap / Sales | 2.10 | 1.27 | 2.35 | 4.39 | 1.64 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -3.60 | 0.57 | 3.76 | 15.47 | 13.46 |
| Core EBITDA Growth(%) | 294.50 | -84.74 | -45.45 | 22.18 | 35.03 |
| EBIT Growth(%) | 93.58 | -248.67 | -57.33 | 24.06 | 41.56 |
| PAT Growth(%) | 75.72 | -372.49 | -57.14 | 27.31 | 44.25 |
| EPS Growth(%) | 70.40 | -394.57 | -57.09 | 36.53 | 42.79 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.78 | 0.62 | 0.49 | 0.31 | 0.51 |
| Current Ratio(x) | 1.29 | 1.40 | 1.50 | 1.49 | 1.41 |
| Quick Ratio(x) | 0.74 | 0.78 | 0.86 | 0.98 | 0.98 |
| Interest Cover(x) | -0.14 | -2.88 | 4.36 | 6.60 | 3.63 |
| Total Debt/Mcap(x) | 0.16 | 0.22 | 0.09 | 0.04 | 0.18 |
Compare Financial Ratios of peers of SEQUENT SCIENTIFIC
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SEQUENT SCIENTIFIC | ₹4,481.6 Cr | -7.2% | -5.6% | 24.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹424,382.0 Cr | -3.7% | -2.5% | 31.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,224.0 Cr | 2.3% | 2.1% | 46.9% | Stock Analytics | |
| CIPLA | ₹116,943.0 Cr | -3.2% | 0% | 8.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,588.0 Cr | -2.4% | 7.3% | 15.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹100,704.0 Cr | 2% | 2.3% | 37.9% | Stock Analytics | |
SEQUENT SCIENTIFIC Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SEQUENT SCIENTIFIC | -7.2% |
-5.6% |
24.2% |
| SENSEX | -2.2% |
-5.9% |
7.2% |
You may also like the below Video Courses
